← Leaderboards
Atul Bedi
Johns Hopkins University
$5,354,046
Attributed
$6,194,421
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $698.3K · FY2005–18$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$6,194,421 · 6
By mechanism
R01$4,538,721 · 3
P50$1,418,796 · 2
R29$236,904 · 1
Top collaborators
- Rajani Ravi5 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Joel L Pomerantz$11,012,268
- John Nicholas$16,258,113
- Karen L. Beemon$8,952,439
- William M Baldwin$16,703,281
- Richard F. Ambinder$9,273,650
Others in their field
Top investigators on “Effector Cell”
- Michael S. Diamond · University Of Pittsburgh At Pittsburgh$45,507,937
- Rafi Ahmed · Emory University$40,549,730
- Louis J. Picker · Oregon Health And Science University$40,412,418
- Arlene H Sharpe · Harvard Medical School$39,916,440
- Jeffrey Victor Ravetch · Rockefeller University$35,982,041
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$33,132,961
Research focus
Effector CellIn VivoImmuneTumorEpidermal Growth Factor ReceptorReceptorCetuximabNeoplastic CellApoptosisSignal TransductionResponseMediatingCessation Of LifeCytotoxicDna DamageAttenuatedT-LymphocyteNatural Killer CellsImmunologic SurveillanceImmune ResponseImmune SystemMonoclonal AntibodiesLigandsCd8b1 Gene
Grant awards (21)
Bifunctional Immunostimulatory Antibodies for Treatment of Breast Cancer$336,150
R01 · FY2018 · CA · contact PI
Bifunctional Immunostimulatory Antibodies for Treatment of Breast Cancer$336,150
R01 · FY2017 · CA · contact PI
Improving epidermal growth factor receptor-targeted of HNSCC by inhibition of tr$361,939
P50 · FY2016 · DE · contact PI
Bifunctional Immunostimulatory Antibodies for Treatment of Breast Cancer$336,150
R01 · FY2016 · CA · contact PI
Improving epidermal growth factor receptor-targeted of HNSCC by inhibition of tr$362,136
P50 · FY2015 · DE · contact PI
Bifunctional Immunostimulatory Antibodies for Treatment of Breast Cancer$336,150
R01 · FY2015 · CA · contact PI
Bifunctional Immunostimulatory Antibodies for Treatment of Breast Cancer$336,150
R01 · FY2014 · CA · contact PI
Improving epidermal growth factor receptor-targeted of HNSCC by inhibition of tr$374,233
P50 · FY2013 · DE · contact PI
Improving epidermal growth factor receptor-targeted of HNSCC by inhibition of tr$320,488
P50 · FY2012 · DE · contact PI
Using Targeted Immunotherapy to Enhance Chemotherapy of Colorectal Cancer$302,252
R01 · FY2011 · CA · contact PI
Using Targeted Immunotherapy to Enhance Chemotherapy of Colorectal Cancer$311,600
R01 · FY2010 · CA · contact PI
Using Targeted Immunotherapy to Enhance Chemotherapy of Colorectal Cancer$311,600
R01 · FY2009 · CA · contact PI
Using Targeted Immunotherapy to Enhance Chemotherapy of Colorectal Cancer$311,600
R01 · FY2008 · CA · contact PI
Using Targeted Immunotherapy to Enhance Chemotherapy of Colorectal Cancer$311,283
R01 · FY2007 · CA · contact PI
Death Receptor-Induced Apoptosis of B-Cell Malignancies$327,409
R01 · FY2005 · CA
Death Receptor-Induced Apoptosis of B-Cell Malignancies$327,409
R01 · FY2004 · CA
Death Receptor-Induced Apoptosis of B-Cell Malignancies$327,409
R01 · FY2003 · CA
Death Receptor-Induced Apoptosis of B-Cell Malignancies$327,409
R01 · FY2002 · CA
Treatment of lymphoma by death receptor induced apoptosis$0
P50 · FY2002 · CA
P34 CDC2 IN APOPTOSIS AND GENETIC INSTABILITY OF CANCERS$120,206
R29 · FY2001 · CA
P34 CDC2 IN APOPTOSIS AND GENETIC INSTABILITY OF CANCERS$116,698
R29 · FY2000 · CA